PFKFB3 and neoplasm: In addition, the glycolysis inhibitor 2-deoxyglucose (2-DG) or 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3, a key glycolytic enzyme) can effectively reduce the expression of CAXII mRNA and protein levels in HepG2 tumor culture supernatant (TSN)-treated monocytes (peripheral blood purified CD14+ cells from healthy subjects) (45, 46).